NuCana Appoints Martin J Birkhofer, M.D. as Chief Medical Officer

23-Jun-2015 - United Kingdom

NuCana, a clinical stage biopharmaceutical company, announced the appointment of Martin J Birkhofer, M.D. as Chief Medical Officer and the opening of a US office in Princeton, New Jersey.

Dr Birkhofer, an oncologist by training, joins NuCana from inVentiv Health Clinical, a leading global supplier of drug development services, where he led its global medical and scientific affairs and held the title of Chief Medical Officer. Between 1994 and 2013, he served in various leadership roles within Research and Development and Business Development at Bristol-Myers Squibb (BMS), including Vice President, Search, Evaluation and Diligence, Vice President Oncology Global Medical Affairs, Vice President Product Development for Erbitux, Executive Director of Oncology Clinical Research Europe and Executive Director Clinical Pharmacology. He brings to NuCana a broad drug development experience, and the knowhow of the evolving access, reimbursement and commercialisation environment for oncology products.

Dr Birkhofer is Board Certified in Internal Medicine and Medical Oncology. He obtained his M.D. from New York Medical College in Valhalla, New York.

With the hiring of Dr Birkhofer, NuCana is also announcing the opening of its U.S. office in Princeton, New Jersey, which will establish a U.S. presence for the company and support NuCana's international clinical study programmes and other activities.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances